Products - Children and young people | Topic | NICE

Showing 15 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Depression in children and young people: identification and management (NG134)
Product type:
Guidance
Programme:
NICE guideline
Published date:
25 June 2019
Fever in under 5s: assessment and initial management
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 November 2019
Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome [ID1308]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 December 2019
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Babies, children and young people's experience of healthcare
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Looked-after children and young people
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 April 2021
Children and young people with disabilities & severe complex needs: integrated health & social care support & service guidance
Status:
In development
Programme:
NICE guideline
Expected publication date:
12 May 2021
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
28 May 2021
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
2 June 2021
Self-harm in over 8s: management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 January 2022
Fenfluramine for treating Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC